Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent
Authors:
- Charles P. HeiseCHCharles P. Heise
- Diane E. HaszDHDiane E. Hasz
- Marcela ZebedeMZMarcela Zebede
- Sandra M. KellySKSandra M. Kelly
- Roy CurtissRCRoy Curtiss
- Arnold S. LeonardALArnold S. Leonard
- Peter M. AndersonPAPeter M. Anderson
- 1 April 1996
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 11 (2) , 145-153
Abstract
Currently, there is no long-term effective treatment for unresectable hepatic malignancies. Salmonella sp. are known to naturally track to the liver during active infection. To develop a biological vector for delivery of Interleukin-2 (IL-2) to the liver for anti-tumor purposes, the avirulent and highly immunogenic χ4550 strain of Salmonella typhimurium was used as a vector for IL-2. The gene for human IL-2 was cloned into plasmid pYA292 (renamed pIL-2) and inserted into the attenuated Salmonella typhimurium and renamed [χ4550 (pIL-2)]. This transformant was found to produced biologically active IL-2 demonstrated by NK cell activation in a 4 hour chromium release cytotoxicity assay. To determine anti-tumor potential, MCA-38 murine adenocarcinoma cells were injected intrasplenically into C57BL/6 mice to produce hepatic metastases and metastases were subsequently enumerated after 12 days. Statistical significance was determined by ANOVA with Fisher's test for significance. Hepatic metastases enumerated by blinded observers revealed that the mean number of metastases was 106.4 in control mice, 103.7 in mice gavage fed attenuated salmonella without IL-2 [χ4550(pYA292)], and 44.3 in mice fed the χ4550(pIL2); (ANOVA: p<0.01). Culture of livers and spleens in mice administered a single gavage dose of salmonella demonstrated persistent colonization for up to 4 weeks. No observable toxicity was seen to either IL-2 or salmonella. These studies demonstrate that the χ4550(pIL2) is a novel form of in vivo biotherapy which produces biologically active IL-2 and employs the oral route of administration to stimulate an immune response against malignancy in the liver.Keywords
This publication has 10 references indexed in Scilit:
- Surgical options in the treatment of hepatic metastasis from colorectal cancerCurrent Problems in Surgery, 1995
- Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2Clinical Pharmacokinetics, 1994
- Systemic and mucosal immune responses in mice orally immunized with avirulent Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutininInfection and Immunity, 1994
- Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccinationInfection and Immunity, 1994
- Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteersInfection and Immunity, 1992
- A ‘safe-site’ for Salmonella typhimurium is within splenic cells during the early phase of infection in miceMicrobial Pathogenesis, 1991
- The IL‐2 mediated amplification of cellular cytotoxicityJournal of Cellular Biochemistry, 1991
- Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine StrainNature Biotechnology, 1988
- Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenicInfection and Immunity, 1987
- Plasmid-associated virulence of Salmonella typhimuriumInfection and Immunity, 1987